(NASDAQ: VERA) Vera Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 114.66%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.02%.
Vera Therapeutics's revenue in 2026 is $0.On average, 14 Wall Street analysts forecast VERA's revenue for 2026 to be $3,005,641,951, with the lowest VERA revenue forecast at $809,648,956, and the highest VERA revenue forecast at $8,235,213,462. On average, 12 Wall Street analysts forecast VERA's revenue for 2027 to be $16,547,140,603, with the lowest VERA revenue forecast at $8,922,440,172, and the highest VERA revenue forecast at $31,669,324,616.
In 2028, VERA is forecast to generate $34,588,280,109 in revenue, with the lowest revenue forecast at $14,989,852,916 and the highest revenue forecast at $55,460,154,378.